Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $53202.0.

  • InMed Pharmaceuticals' Depreciation & Amortization (CF) fell 252.29% to $53202.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $211462.0, marking a year-over-year decrease of 359.48%. This contributed to the annual value of $212839.0 for FY2025, which is 307.88% down from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Depreciation & Amortization (CF) is $53202.0, which was down 252.29% from $52752.0 recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Depreciation & Amortization (CF) peaked at $55231.0 during Q4 2023, and registered a low of $28532.0 during Q3 2021.
  • For the 5-year period, InMed Pharmaceuticals' Depreciation & Amortization (CF) averaged around $51385.1, with its median value being $53203.0 (2024).
  • Per our database at Business Quant, InMed Pharmaceuticals' Depreciation & Amortization (CF) soared by 7190.52% in 2022 and then crashed by 497.0% in 2023.
  • InMed Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $49797.0 in 2021, then fell by 1.5% to $49049.0 in 2022, then increased by 12.6% to $55231.0 in 2023, then dropped by 3.67% to $53203.0 in 2024, then decreased by 0.0% to $53202.0 in 2025.
  • Its Depreciation & Amortization (CF) was $53202.0 in Q3 2025, compared to $52752.0 in Q2 2025 and $52305.0 in Q1 2025.